New York City | Louisville, Ky. | Pittsburgh
Join a SITC Professional Interest Community
Create new collaborations, build your professional network and discuss the latest research trends in SITC Professional Interest Communities.
The Journal for ImmunoTherapy of Cancer (JITC) received its first impact factor of 8.374! JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
See members discuss the benefits of a SITC membership in this new video.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
The cited editorial states that even with modest survival benefits, tripling of PFS as related to the PACIFIC trial of use of durvalumab immediately after chemoradiotherapy is commendable. Given minimal side effects, its addition should be considered ...
Dear Colleagues ,
Sidra Medicine is proud to host Qatar's first International Workshop on Engineered Immune Cells in Cancer Immunotherapy (EICCI): from Discovery to "Off-the shelf" Development.
Translating the potency of the anti-cancer immune ...
Dear Colleagues ,
It is our distinct pleasure to invite you to attend the Global Conference on Cancer & Oncology Research taking place at Dubai, UAE.
Date: Monday 04 and Tuesday 05 March 2019
Venue: Radisson Blu Hotel, Dubai Waterfront ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org